Basic information Safety Supplier Related

CWP232228

Basic information Safety Supplier Related

CWP232228 Basic information

Product Name:
CWP232228
Synonyms:
  • CWP232228
  • CWP232228?sodium
  • CWP232228 disodium
  • Beta catenin,Wnt,Breast,β-catenin,Inhibitor,CWP232228,CWP 232228,cells,signaling,stem,Cancer,inhibit,liver,CWP-232228
  • Sodium 4-(((6S,9aS)-2-allyl-1-(benzylcarbamoyl)-8-((2-methyl-2H-indazol-7-yl)methyl)-4,7-dioxooctahydro-1H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl phosphate
CAS:
1144044-02-9
MF:
C33H37N7NaO7P
MW:
697.66
Mol File:
1144044-02-9.mol
More
Less

CWP232228 Chemical Properties

form 
Solid
color 
White to off-white
InChIKey
RCZZPLXBWBXLAA-RYRAPZCFNA-N
SMILES
C(N1N(CC(=O)N2[C@H](C(=O)N(CC3=CC=CC4=CN(C)N=C34)C[C@]12[H])CC1C=CC(OP(O)(O)=O)=CC=1)CC=C)(=O)NCC1C=CC=CC=1.[NaH] |&1:7,23,r|
More
Less

CWP232228 Usage And Synthesis

Uses

CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs)[1].

in vivo

CWP232228 (100 mg/kg, administered i.p.; daily; 21days for mice bearing 4T1 cell tumors; 60 days for mice bearing MDA-MB-435 cell tumors) results in a significant reduction in tumor volume[1].

Animal Model:7-week-old female Balb/c and NOD/SCID mice bearing 4T1 or MDA-MB-435 cell tumors[1]
Dosage:100 mg/kg
Administration:Administered i.p.; daily; 21days for mice bearing 4T1 cell tumors, 60 days for mice bearing MDA-MB-435 cell tumors
Result:Treatment resulted in a significant reduction in tumor volume.

References

[1] Jang GB, et al. Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells. Cancer Res. 2015 Apr 15;75(8):1691-702. DOI:10.1158/0008-5472.CAN-14-2041
[2] Kim JY, et al. Oncotarget. 2016 Apr 12;7(15):20395-409. CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment. DOI:10.18632/oncotarget.7954

CWP232228Supplier

Shanghai fuxiang biotechnology co., ltd Gold
Tel
13611719524
Email
2674347328@qq.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Shanghai Yu Ben Biotechnology Co., Ltd.
Tel
021-61350663 15502154572
Email
1639466865@qq.com